1. Introduction {#s0005}
===============

Phenylketonuria \[PKU, MIM [261600](261600){#ir0005}, also referred to as phenylalanine hydroxylase (PAH; EC 1.14.16.1) deficiency\] is a rare (prevalence \< 1/10,000--1/15,000 births) autosomal recessive disorder characterized by an impairment of the body\'s ability to metabolize phenylalanine (Phe) [@bb0005]. Without a fully functional PAH enzyme, Phe accumulates in the blood, brain, and body tissues. High concentrations of blood Phe are toxic to the central nervous system and can cause severe neurological complications and intellectual disability [@bb0010]. The new treatment guidelines of the American College of Medical Genetics and Genomics (ACMG) state that the clinical treatment goal for individuals with PKU are to maintain blood Phe within the range of (120--360 μmol/L) for individuals of all ages and that treatment should be lifelong [@bb0010].

Newborn screening for PKU was instituted in the 1960s to prevent the most serious consequences of the disease [@bb0010], [@bb0015]. Dietary treatment \[including the use of Phe-free medical foods and the avoidance of high protein foods\] successfully lowers blood Phe in most individuals with PKU [@bb0020]. Pharmaceutical treatments include the use of sapropterin dihydrochloride (a synthetic form of tetrahydrobiopterin (BH4) --- the natural co-factor for the PAH enzyme). Studies have shown that sapropterin dihydrochloride is well tolerated, lowers blood Phe, and improves Phe tolerance in approximately 25--50% of individuals with PKU [@bb0010], [@bb0025].

There are substantial unmet needs of individuals with PKU [@bb0030]. Lifetime adherence to a Phe-restricted diet is challenging and blood Phe is difficult to maintain within the recommended range. Even individuals who successfully manage their blood Phe from birth can exhibit subtle deficits in neuropsychological functioning [@bb0035], anxiety, depression, and executive function deficits can occur even in those individuals who are well controlled [@bb0010]. Therefore, new therapies are needed to improve the quality of life of individuals with PKU across their lifespans [@bb0040].

The National PKU Alliance (NPKUA) is a patient advocacy nonprofit organization dedicated to improving the lives of individuals with PKU and assisting in the development of a cure. Formed in 2008 by 17 state and regional support groups across the country, the NPKUA focuses on critical and unmet needs of the PKU patient community. Patient advocacy organizations (like NPKUA) are important because they disseminate reliable information about new treatments to affected individuals and their families [@bb0045]. The NPKUA provides information and support to adults and families of children with PKU, advocates for the reimbursement of Phe-free and modified low-protein foods, and invests in targeted and peer reviewed research for the development of new therapies and a future cure for PKU.

The NPKUA conducted a survey of adults and children with PKU in the United States to better understand the current and future needs of the PKU community. The goal of the survey was to help inform the NPKUA\'s research priorities, provide feedback from individuals to medical providers, payers, and other stakeholders, and to serve as a resource to industry to ensure the patient perspective is central to the development of new therapies.

2. Methods {#s0010}
==========

The NPKUA conducted a self-selected, non-randomized patient survey during May--June 2015 that focused on current therapy status, treatment preferences, and risk tolerance for new treatments. The survey consisted of 28 questions, 21 primary questions and 7 supplemental questions that asked for either categorical, free form, or Likert-scale responses ([Table 1](#t0005){ref-type="table"}). A link to an online survey was distributed to NPKUA members and families via e-mail, posted on the PKU listserv, posted on the NPKUA\'s Facebook page, and sent out via e-mail to addresses collected through the [PKU.com](http://PKU.com){#ir0010} website. If more than one child had PKU in a household, parents and caregivers were asked to respond to the survey using their experience of the oldest child with PKU.

2.1. Statistical analysis {#s0015}
-------------------------

Response rates were computed using the number of respondents to each survey question. Some responses required the responder to self-report their data according to interval ranges, other responses used Likert-Scales, and some responses permitted free-form entries. Similar Likert-Scale responses were combined to simplify the statistics (e.g., 'very easy', 'easy', and 'somewhat easy' responses were combined into a single group). Information regarding gender, BMI, and highest lifetime Phe was not requested. An ANOVA test was used to compare group means using 95% confidence intervals.

3. Results {#s0020}
==========

3.1. Survey response {#s0025}
--------------------

From a pool of 6312 potential respondents, at total of 625 (9.9%) responded to the survey. Respondents included individuals with PKU (N = 220), parents of children with PKU (N = 362), other caregivers (N = 39), and others (N = 4). Of the 21 primary questions, 19 had a response rate of 74% (N = 465) or higher and 13 questions had a response rate of 96% (N = 606) or higher. Respondents were almost evenly divided by age. About half of respondents (53%, 332/622) were ≤ 18 and half (47%, 290/622 were \> 18 years of age.

3.2. Current PKU clinical status {#s0030}
--------------------------------

Over half (61.8%, 383/620) of those surveyed said that they had their blood drawn to monitor blood Phe concentrations in the last month. More than two-thirds (68.4%, N = 423) stated that they desired blood Phe within the ACMG range of 120--360 μmol/L. However, less than half (46.7%; 288/617) managed to attain Phe within this range. There was a difference in Phe control by age. [Fig. 1](#f0005){ref-type="fig"} shows that individuals with PKU ≤ 18 years were 3-times as likely to have blood Phe within the 120--360 μmol/L range compared to adults \> 18 years. [Fig. 1](#f0005){ref-type="fig"} also shows that Phe concentrations \> 360 μmol/L were reported for one-quarter of ≤ 18 year old individuals and almost two-thirds of \> 18 year old individuals. For individuals with blood Phe concentrations \> 360 μmol/L, the mean for ≤ 18 year old individuals (447.6 ± 116.5 μmol/L, N = 63) was not significantly different compared to \> 18 year old individuals (477.0 ± 120.3 μmol/L, N = 160).

3.3. Current PKU therapy {#s0035}
------------------------

Overall, 70% of survey respondents reported consumption of medical formula, 54% consumed modified low-protein foods, 76% consumed foods that are naturally low in protein, 40% used sapropterin dihydrochloride, 3% were prescribed large neutral amino acids (LNAA), while 6% stated they are currently not treating PKU with medical foods or pharmacotherapy. Younger individuals reported consuming medical foods more than adults. Sapropterin dihydrochloride use was not associated with subject age.

Fifty-eight percent of individuals with blood Phe \< 360 μmol/L reported clinic visits within the past year compared to 38.6% of individuals with blood Phe \> 360 μmol/L. Eight-percent of respondents reported that it had been more than two years since their last clinic visit. Individuals on sapropterin dihydrochloride therapy generally had more recent metabolic clinic visits; however, most individuals (86.3%) reported visiting a metabolic clinic within the past year. About two-thirds (68%) of respondents said that they had followed their PKU treatment plan for all or most of their life.

[Fig. 2](#f0010){ref-type="fig"} shows that about a third of respondents reported that managing their PKU was easy, while half reported that PKU management was difficult. Similarly, two-thirds reported that PKU restricted their lifestyle. More adults reported struggling with their treatment plan than children. Almost half (49.5%) of individuals with blood Phe within the recommended range reported that their PKU was easy to manage compared to 20.7% of individuals with blood Phe \> 360 μmol/L. More individuals on sapropterin dihydrochloride reported that their PKU was easy to manage when compared to individuals on other treatments (p \< .0001) and sapropterin dihydrochloride use was associated with lower blood Phe (p \< .0001).

3.4. Future therapy and treatments {#s0040}
----------------------------------

When asked about the importance of new treatments, 474 individuals responded. A majority (91.4%, N = 433) of those responding stated that it was 'somewhat important', 'important', or 'very important' to develop new treatments for PKU, 4.2% (N = 20) were neutral on the topic, and 4.5% (N = 21) stated that new treatments were not important. When the responses were subdivided by subject blood Phe the desire for new treatment did not depend on the concentration of blood Phe. The majority (92.7%, 202/218) of individuals with blood Phe between 120 and 360 μmol/L stated that new treatments were important as did 89.9% (187/208) of individuals with blood Phe \> 360 μmol/L.

Respondents were asked to select a statement that best reflected their feeling about their current PKU treatment plan and their hopes for the future. Over half (57%) responded that they were happy with their current treatment plan but hoped that new treatments would be available in the future. About a third (35%) stated that they struggle with the current treatment plan or have no current treatment plan but also hope for new treatments.

[Table 2](#t0010){ref-type="table"} shows the survey results when respondents were asked which symptoms of PKU they would like to improve as a benefit of new treatments. A total of 463 individuals responded and reported that blood Phe reduction, improved attention, and improved executive function were the most important potential benefits of new treatments. Results were consistent when the responses were subdivided by subject blood Phe. Eighty-two (82%, 169/206) percent of individuals with blood Phe 120--360 μmol/L desired treatments that had the potential to lower blood Phe whereas 95% (200/211) of individuals with blood Phe \> 360 μmol/L desired this same benefit.

[Table 3](#t0015){ref-type="table"} shows respondent preferences regarding which lifestyle improvements they considered most desirable in the context of future treatments --- and over three-fourths (77.7%) desire a treatment that allows for an increase in natural protein intake without an increase in symptoms.

3.5. Benefit/risks and adverse events related to new treatments {#s0045}
---------------------------------------------------------------

Respondents were asked to describe their interest in therapeutic administration of new therapies using a 7-point Likert scale (from 'not at all interested' to 'extremely interested'). [Table 4](#t0020){ref-type="table"} shows that respondents prefer oral ingestion for new therapies and dislike injections. Injections at home were preferred over injections at a medical facility --- and half stated no interest in daily injections at a medical facility.

[Table 5](#t0025){ref-type="table"} shows the results of willingness to tolerate at least some temporary injection site pain (81%) or mild skin irritation (79%). However, internal bleeding and severe allergic reactions were generally considered intolerable side effects. Two-thirds (66.8%) were willing to tolerate immunosuppressant drugs for ≤ 6 months, 56.3% for ≤ 1 year, 29.7% for ≤ 5 years, and 22.6% for ≤ 10 years.

4. Discussion {#s0050}
=============

With the advent of newborn screening and the development of medical foods and dietary therapy, severe mental retardation due to PKU has abated. This progress has resulted in significant economic gains to society as well as improvements in quality of life and health benefits for affected individuals [@bb0010]. Many clinicians and health care organizations may hold the view that, for individuals with PKU, current strategies and therapies are therefore adequate and further healthcare investment is no longer needed.

In contrast to this view, these NPKUA survey data show that many individuals with PKU report difficultly managing their disease, have problems maintaining their blood Phe concentrations within the recommended range, and that the ability to control blood Phe worsens with age. Managing PKU is difficult, complex, and life-long. There are substantial challenges for individuals with PKU including compliance with a Phe-restricted diet, limited therapeutic options, side effects of existing treatments, lack of insurance coverage for medical foods, non-reimbursed costs, and a need for palatable alternatives [@bb0030], [@bb0050]. Adults with PKU face even more challenges and comorbidities [@bb0055].

The survey data confirm that dietary therapy remains the mainstay of clinical treatment with three-quarters of the cohort consuming natural low-protein foods. More individuals on sapropterin dihydrochloride reported that their PKU was easier to manage when compared to those not receiving sapropterin dihydrochloride (p \< .0001) and sapropterin dihydrochloride use was associated with lower blood Phe (p \< .0001). However, responsiveness to sapropterin dihydrochloride varies from 25 to 50% of individuals with PKU [@bb0010]. The majority of surveyed individuals stated that development of new treatments and therapies is an important goal. [Table 2](#t0010){ref-type="table"} shows that the most desired outcomes for new treatments would reduce blood Phe concentrations, improve attention, and improve executive function. Respondents preferred oral administration of any newly developed therapies with desired outcomes of a lower blood Phe and improvement in neuropsychological performance. Injections at home were preferred over injections at a medical facility --- half (50.1%) have no interest in daily injections at a medical facility. This information may be pertinent to current trials of rAvPAL-PEG, which is administered by injections with concomitant mild to moderate skin and injection site adverse events [@bb0030].

Blood Phe is a compliance measure for PKU clinical treatment as well as a biomarker of disease severity. Only about half of survey respondents reported blood Phe within 120--360 μmol/L -- the ACMG recommended range -- even though most were knowledgeable about this guidance. [Fig. 1](#f0005){ref-type="fig"} shows that younger (≤ 18 years) individuals were 3-times as successful in keeping their blood Phe concentrations within the recommended clinical range compared with adults. High blood Phe was reported more often for adults and less often in children and adolescents. These data confirm previous studies that difficulty managing PKU increases with age [@bb0060], [@bb0065], [@bb0070]. In early childhood, PKU dietary compliance is often high due to high parental control and low peer pressure; however dietary compliance generally decreases in adolescence and adulthood [@bb0075]. Reinstatement of dietary therapy after discontinuation in adolescence or adulthood can be extremely difficult [@bb0080]. In adults, lack of insurance coverage for medical foods the temptation of eating high protein foods once the patient has developed a taste for them, insufficient knowledge of PKU, and socio-economic status are likely influences for adherence to the very difficult PKU diet.

These survey data have several limitations --- most of which are typical of survey questionnaires. The survey data were weighted toward informant-report and had less representation of either self-report or caregiver report. While data were not clinically verified and medical histories were unknown, the blood Phe data are consistent with previous studies [@bb0060], [@bb0065], [@bb0070]. The NPKUA questionnaire was not assessed for reliability or bias (including social desirability bias). Many of the survey questions asked for opinions and not verifiable facts. However, none of the conclusions conflict with published evidence. Survey responders may have been more motivated and compliant than other individuals, which may explain the high rate (86%) of annual clinic visits in this cohort compared to a previous report [@bb0085] as well as the relatively low mean blood Phe even for the group of individuals with blood Phe above 360 μmol/L.

5. Conclusions {#s0055}
==============

Individuals with PKU face a variety of challenges and unmet needs. Even individuals who are conscientious with self-care, and who have adequate Phe control as a result, report difficulties treating their condition and maintaining recommended treatment. The NPKUA survey data show that many individuals with PKU report difficultly managing their disease, have problems maintaining their blood Phe within the recommended range, and that the ability to control blood Phe worsens with age. In addition, many individuals with PKU desire new therapies and treatments with tolerable side effects. Payers, government agencies, clinicians, and industry partners should consider patient input when developing and approving new therapies and treatments for PKU.
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![a, b. Percentage of blood Phe values within the range of \< 120, 120--360, and \> 360 μmol/L for individuals with PKU \> 18 years ([Fig. 1](#f0005){ref-type="fig"}a, N = 286) and ≤ 18 years ([Fig. 1](#f0005){ref-type="fig"}b, N = 329) during the past year.](gr1){#f0005}

![Percentage of respondents reporting that managing PKU treatment was: Easy^1^, Neutral, or Difficult^2^ (N = 615).\
1: Combines Likert scale responses for: 'very easy', 'easy', and 'somewhat easy'\
2: Combines Likert scale responses for: 'somewhat difficult', 'difficult', and 'very difficult'.](gr2){#f0010}

###### 

National PKU Alliance (NPKUA) survey questions and question type.

  Number   Question                                                                                      Response type
  -------- --------------------------------------------------------------------------------------------- ---------------
  Q01      What is your relationship to PKU?                                                             Categorical
  Q02      How old are you when completing this form?                                                    Categorical
  Q03      Select the statements below that reflect how you currently treat your/your loved one\'s PKU   Categorical
  Q04      When was the last time you drew blood to monitor Phe levels?                                  Categorical
  Q05      What has been the average blood Phe level in the last years?                                  Categorical
  Q06      Select preferred blood Phe level                                                              Categorical
  Q07      When was the last visit to a metabolic clinic that focuses on PKU patients?                   Categorical
  Q08      Select the statement below that best reflects your current PKU treatment status.              Categorical
  Q08x     Explain 'Other' current PKU treatment status                                                  Categorical
  Q09      Indicate difficulty managing PKU                                                              Likert
  Q09x     Explain 'Other' difficulty managing PKU                                                       Free form
  Q10      Indicate how PKU restricts lifestyle                                                          Likert
  Q10x     Indicate how PKU restricts lifestyle                                                          Free form
  Q11      Select statement that best reflects current PKU treatment plan                                Categorical
  Q12      Indicate importance of having new PKU treatments                                              Likert
  Q13      What benefits do you hope to see with a new PKU treatment?                                    Free form
  Q14      What symptoms or results would you like to see with a new PKU treatment?                      Categorical
  Q14x     Explain 'Other' symptoms or results with new treatment                                        Free form
  Q15      Rank the symptoms or results from Question 14                                                 Likert
  Q15x     Force Rank the symptoms or results from Question 14                                           Likert
  Q16      What change in lifestyle would you like to see having a new PKU treatment?                    Categorical
  Q16x     Explain 'Other' change in lifestyle                                                           Free form
  Q17      Rank the two top changes in lifestyle from Question 16                                        Likert
  Q17x     Force Rank the two top changes in lifestyle from Question 16                                  Likert
  Q18      Indicate willingness to new PKU treatments                                                    Likert
  Q19      Indicate willingness to tolerate side effects from a new treatment                            Likert
  Q20      Indicate willingness to take immunosuppressant each time period                               Likert
  Q21      Please tell us anything else you would consider in deciding to choose a new therapy for PKU   Free form

x: Questions with an 'x' relate to the immediately preceding question and denote either a corollary question or a request for more information.

###### 

Ranked responses for most desired outcomes when considering new treatments.

  Desired individual preferences                                                             Response percent   Response count
  ------------------------------------------------------------------------------------------ ------------------ ----------------
  Drop in blood Phe concentrations                                                           87.5%              405
  Improved attention span and ability to focus                                               65.7%              304
  Improved executive function skills, such as the ability to plan, organize and prioritize   61.6%              285
  Reduced depression, anxiety and/or ups and downs in overall mood                           55.1%              255
  Improved processing speed --- the ability to start and complete tasks                      52.1%              241
  Increase in energy                                                                         51.0%              236
  Improved memory                                                                            49.5%              229
  Lifting of "the fog"                                                                       43.0%              199
  Reduced bone loss                                                                          30.0%              139
  Reduced tremors                                                                            19.2%              89
  Reduced other damage such as muscle weakness, and gait disorders                           18.8%              87

###### 

Ranked responses when asked which lifestyle improvements were most desired.

  Preferences                                                                                    Response percent   Response count
  ---------------------------------------------------------------------------------------------- ------------------ ----------------
  I would like to be able to increase my protein intake without increasing my symptoms of PKU.   77.7%              365
  I would like to be able to eat any foods I choose regardless of their protein content.         76.0%              357
  I would like to be able to consume less of my medical foods (formula and low protein foods).   57.7%              271
  I would like to discontinue the use of my medical foods (formula and low protein foods).       47.2%              222
  I would like to have better mental health.                                                     45.7%              215
  I would like to improve my social relationships.                                               34.5%              162
  I would like to decrease the frequency of blood tests.                                         28.9%              136

###### 

Ranked Responses when Asked their Degree of Interest in the Method of Administration of New Therapies.

  Methods of therapeutic administration                                           No interest (%)   Neutral (%)   Some or strong interest (%)
  ------------------------------------------------------------------------------- ----------------- ------------- -----------------------------
  Weekly consumption of a probiotic                                               1.7               7.2           91.1
  Daily oral pill(s)                                                              3.9               7.6           88.5
  Daily consumption of a probiotic                                                2.8               9.5           87.7
  Monthly injection at home                                                       9.3               4.8           85.9
  Inserting a gene into your cells at a medical facility to correct PKU           7.3               7.1           85.7
  Infusion of stem cells over several days at a medical facility to correct PKU   8.1               9.2           82.7
  Weekly injection at home                                                        14.0              5.7           80.3
  Monthly injection at a medical facility                                         16.0              7.0           76.9
  Daily injection at home                                                         21.7              8.1           70.2
  Weekly injection at a medical facility                                          37.7              7.8           54.5
  Daily injection at a medical facility                                           50.1              8.0           41.9

###### 

Ranked responses by tolerance for side effects from a new therapy or treatment.

  Possible treatment side effect                              Some intolerance (%)   Neutral (%)   Some tolerance (%)
  ----------------------------------------------------------- ---------------------- ------------- --------------------
  Temporary injection site pain                               11.9                   7.1           81.0
  Mild skin irritation (slight redness)                       13.4                   7.6           79.0
  Temporary allergic reaction at injection site               24.7                   10.8          64.5
  Moderate skin irritations (redness with swelling/itching)   24.8                   11.4          63.7
  Mild headache                                               29.9                   13.4          56.6
  Mild upset stomach                                          34.8                   14.3          51.0
  Mild nausea                                                 43.3                   14.4          42.2
  Moderate headache                                           47.1                   13.7          39.3
  Mild joint pain                                             50.5                   11.1          38.3
  Moderate upset stomach                                      51.5                   12.8          35.7
  Mild chills/shaking chills                                  52.2                   12.7          35.2
  Moderate nausea                                             56.7                   12.3          31.1
  Moderate chills/shaking chills                              60.2                   11.4          28.4
  Moderate joint pain                                         64.0                   9.1           26.9
  Severe allergic reaction that requires medical attention    88.7                   5.0           6.3
  Risk of internal bleeding                                   92.2                   3.3           4.6
